g12c

Sotorasib (AMG-510) is an orally active and selective covalent inhibitor of KRAS G12C. Sotorasib binds to the GDP state of the inactive conformation of KRAS G12C and inhibits KRAS and its downstream signaling. Sotorasib exhibits inhibitory activity against KRAS G12C mutant tumors.

Adagrasib (MRTX849) is an orally active and selective covalent inhibitor of KRAS G12C. Adagrasib binds to the GDP state of the inactive conformation of KRAS G12C and inhibits KRAS and its downstream signaling. Adagrasib exhibits inhibitory activity against KRAS G12C mutant tumors.

ARS-853 is an inhibitor of K-RASG12C(IC50 : 2.5 μM), a mutant form of K-RAS that accumulates in the active GTP-bound state in certain cancer cells

KRAS G12C inhibitor 16 is a potent inhibitor of KRAS G12C.

K-Ras(G12C) inhibitor 9 is an allosteric inhibitor of oncogenic K-Ras(G12C).

KRas G12C inhibitor 1 is a compound that selectively inhibits the KRas G12C protein.

K-Ras G12C-IN-4, is a potent Covalent Inhibitor of KRASG12C..

K-Ras(G12C) inhibitor 6 is an irreversible, allosteric inhibitor of the K-Ras(G12C) mutant, achieving 100% protein modification at 10 μM after 24 hours in vitro.

K-Ras(G12C) inhibitor 12 is an allosteric inhibitor of the oncogenic K-Ras(G12C) protein.

PROTAC KRAS G12C degrader-2 (compound 432) acts as a bifunctional modulator, enhancing the hydrolysis of K-Ras protein. One end of this compound features a cereblon inhibitor of apoptosis proteins (IAP), while the other end contains a moiety that binds to KRAS [1].

KRas G12C inhibitor 3 is a compound that specifically inhibits the KRas G12C mutation.

KRas G12C inhibitor 4 is a compound that inhibits KRas G12C.

KRAS G12C inhibitor 22 is a specific inhibitor of the KRAS G12C mutation.

KRAS G12C Inhibitor 37, a potent inhibitor of KRAS G12C, targets the Ras family of proteins, crucial for intracellular signaling related to growth and development. This compound holds potential for research into cancers mediated by KRAS G12C.

KRAS G12C inhibitor 20 is an inhibitor specifically targeting the KRAS G12C mutation.

KRAS G12C inhibitor 34 is an inhibitor of KRAS G12C that can be used to study cancer research.

PROTAC KRAS G12C Degrader-3 (Comp 283) serves as a potent degrader of KRAS G12C, utilized in cancer research [1].

KRAS G12C inhibitor 43 is a potent inhibitor of KRAS G12C and inhibits the migration and proliferation of H358 cells (IC50: 0.001-1 μM μM), A549 cells (IC50>1 μM) and HCC cells (IC50>1 μM).

Heterocyclic compounds as covalent inhibitors of G12C mutant K-Ras protein useful for treating cancers.K-Ras G12C-IN-3 is a novel and irreversible inhibitor of mutant K-ras G12C.

K-Ras G12C-IN-1 is a novel, irreversible inhibitor of mutant K-Ras G12C.

K-Ras G12C-IN-2 is a covalent KRAS G12C inhibitor.

KRAS G12C inhibitor 17 is a potent inhibitor of the KRAS G12C protein.

PROTAC KRAS G12C degrader-1, a cereblon-based degrader, promotes CRBN KRAS G12C dimerization and facilitates the degradation of GFP-KRAS G12C in reporter cells [1].

KRAS G12C inhibitor 21 is a specific inhibitor targeting the KRAS G12C mutation.